You are here: Home » Current Affairs » News » Health
Business Standard

Scientists identify new protein to treat flu symptoms, cut down death risk

Effect of retrocyclin-101 (RC-101) protein was tested on human cells

Topics
Flu

Press Trust of India  |  Washington 

flu treatment, flu, influenza
Thousands die every year due to complications related to influenza despite the widespread use of vaccines, say researchers. (Image for representative purpose) 

Scientists have identified a protein that can improve symptoms influenza as well as reduce the death risk associated with the infection, and possibly other types of diseases.

The protein called retrocyclin-101 (RC-101) is unique in that it not only targets the virus itself, but it also acts upon the harmful inflammation the virus triggers in the host.

While the effect of RC-101 has been studied as a treatment in cells before, it has never been studied in animals.

"Every year, thousands of people across the country die from the or its complications - despite widespread use of annual influenza vaccines," said Daniel J Prantner, a research associate at the University of Maryland in the US.

"We think that this protein could lead to medicines that could be a powerful tool in the battle against this disease, and against inflammation in general," said Prantner.

For the study, published in the Journal of Leukocyte Biology, researchers studied the effects of RC-101 on human cells, and in an animal model of flu, using mice.

They studied human immune cells and found that RC-101 had two positive effects.

First, it blocked the flu virus from infecting the cells; second, it blocked the runway inflammation that is behind most symptoms of influenza infection, such as fever, pain, lethargy, and trouble breathing. This double action is unique, Prantner said.

In the animal model, researchers infected two groups of mice with a dose of influenza that is typically lethal. They gave one of these groups RC-101 two days after infection for a total of five days and gave the other group a placebo.

The mice that were treated with RC-101 exhibited less severe symptoms of the flu and also decreased rates of death.

Among the control group, 90 per cent of the mice died; among the group that was given RC-101, only 20 per cent died.

Although RC-101 does not exist in humans, it does exist in some other animals, including orangutans, and provides powerful antiviral protection.

It appears to have been lost over the course of recent primate evolution. Chimpanzees and gorillas, for example, do not have it.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sun, October 01 2017. 19:05 IST
RECOMMENDED FOR YOU
.